Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit

详细信息    查看全文

• 作者：M. Dos Santos^a ; ^{melanie.dosantos@gmail.com} ; P.E. Brachet^a ; C. Chevreau^b ; F. Joly^a
• 关键词：Metastatic renal cell carcinoma ; Target therapy ; Quality of life ; Patient-reported outcomes ; Clinical benefit ; Randomized clinical trials
• 刊名：Cancer Treatment Reviews
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：53
• 期：Complete
• 页码：53-60
• 全文大小：452 K
• 卷排序：53

文摘

Metastatic renal cell carcinoma is an incurable cancer. Gain in progression-free survival with new drugs is around 3 months. Patient-reported outcomes are an essential endpoint with strong impact on clinical benefit. The quality of the methodology and the data analysis of patient-reported outcomes are not yet optimal. New-generation therapies should demonstrate not only a gain in survival but also in quality of life.